Stock XENOPORT, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases XenoPort, Inc.

Equities

US98411C1009

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for XenoPort, Inc.

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
XenoPort : Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of XenoPort
BU
XenoPort : Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period
BU
Brower Piven Commences an Investigation into the Proposed Sale of XenoPort, Inc. and Encourages Investors to Contact the Firm for Additional Information
BU
Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of XenoPort Inc. - XNPT
PR
Ryan & Maniskas, LLP : Announces Investigation of XenoPort, Inc.
PR
XENOPORT, INC. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Arbor Pharmaceuticals, LLC May Be Unfair to Shareholders
BU
XenoPort : Arbor Pharmaceuticals to Acquire XenoPort
BU
XenoPort : Reports First Quarter Financial Results
BU
XenoPort : to Release First Quarter Financial Results on May 5, 2016
BU
XenoPort : Dr. Reddy's Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829
PU
XenoPort : #StopMakingExcuses Awareness Campaign for Restless Legs Syndrome Launches During Sleep Awareness Week 2016
BU
XenoPort : to Present at the Cowen and Company 36th Annual Health Care Conference
BU
XenoPort : Reports Fourth Quarter and Year-End 2015 Financial Results
BU
XenoPort : to Release Fourth Quarter and Year-End Financial Results on February 25, 2016
BU
XenoPort : Reports Third Quarter Financial Results
BU
XenoPort : to Present at the Credit Suisse Healthcare Conference
BU
XenoPort : to Release Third Quarter Financial Results on November 4
BU
XenoPort : Announces Plan to Focus on its Growing HORIZANT Business and Names Vincent J. Angotti Chief Executive Officer and Director
BU
XenoPort : Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis
BU
XenoPort : to Present at the Morgan Stanley Global Healthcare Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News XenoPort, Inc.
  5. Press Releases